| Model Number |
9004 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Reocclusion (1985)
|
| Date of Event |
04/18/2018
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed 3 additional reocclusion complaints were associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the right mid and distal superficial femoral artery (sfa).Approximately 22 months after the index procedure, the patient¿s right sfa vessel was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Manufacturing review: a lot history review revealed there are a total of 4 complaints for the corporate lot gfap2162.All of the complaints are reported for the allegation of reocclusion.Three of the complaints are not related to this event.The dhr review was conducted and there was nothing found to indicate there was a manufacturing related cause for this event.Investigation summary: the sample was not returned by the user facility.Evaluation could not be performed.It is known approximately 23 months after the index procedure, the patient¿s right sfa vessel was reportedly reoccluded.A revascularization was performed a year later on (b)(6) 2019 and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.Label review: based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.
|
| |
|
Event or Problem Description
|
|
It was reported through a clinical registry that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the right mid and distal superficial femoral artery (sfa).Approximately 22 months after the index procedure, the patient¿s right sfa vessel was reportedly reoccluded.A revascularization was performed and the hcp deemed it was successful.The investigator assessed that the event was not related to the study device or procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.It was further reported that through a clinical registry approximately 23 months post index procedure, lesion was identified occluded.It was further reported that revascularization was performed.
|
| |
|
Search Alerts/Recalls
|